Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
Yongchao Yu,Jin Wang,Dongying Liao,Dou Zhang,Xiaojiang Li,Yingjie Jia,Fanming Kong
DOI: https://doi.org/10.2147/BCTT.S384830
2022-12-09
Breast Cancer: Targets and Therapy
Abstract:Yongchao Yu, 1– 3, &ast Jin Wang, 1– 3, &ast Dongying Liao, 1– 3 Dou Zhang, 1– 3 Xiaojiang Li, 1, 2 Yingjie Jia, 1, 2 Fanming Kong 1– 3 1 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China; 2 National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, People's Republic of China; 3 Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Fanming Kong, Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China, Tel +862227986525, Email Although targeted drugs improved the therapeutic effect of HER2-positive breast cancer, the long-term prognosis was still poor. In this regard, the research and development of antibody-drug conjugates (ADCs) came into being and made a lot of progress. ADCs had the characteristics of both chemotherapeutic agents and targeted agents by combining chemotherapeutic agents and targeted agents through a linker. It not only had a strong anti-tumor effect on HER2-positive breast cancer, but also had certain anti-tumor effects on HER2-low and even HER2-negative patients. In addition, the clinical researches of ADCs combined with immune checkpoint inhibitors (ICIs) therapy had also made a great breakthrough. This review aimed to summarize the clinical progress of ADCs, in particular the two drugs approved by the US Food and Drug Administration (FDA) for HER2-positive metastatic breast cancer as well as to summarize the current status of ADCs in combination with ICIs. Keywords: breast cancer, HER2-positive, antibody-drug conjugates, immunotherapy, advances Breast cancer (BC) had become the most common malignant tumor in women worldwide, accounting for approximately 11.7% of new cancer cases in 2020, which seriously endangered women's health and became the main cause of female death. 1,2 HER2 (human epidermal growth factor receptor-2) is an important biomarker of breast cancer and a member of the ERBB family of tyrosine kinase receptors. It is a transmembrane protein with tyrosine protein kinase activity, which consists of three parts: extracellular ligand binding domain, single strand transmembrane domain and intracellular protein tyrosine kinase domain. 3 When HER-2 binds to the ligand, it activates tyrosine kinase activity mainly by inducing receptor dimerization and autophosphorylation of cytoplasmic tyrosine kinase. The types of variation in HER2 include overexpression, mutation and amplification. 4 At present, the only cancers involved in routine detection and treatment of HER2 targets are gastric cancer and breast cancer. The HER2 criteria used were the same, that is, combined with HER2 protein overexpression and gene amplification to determine HER2 positive. 5 In short, if the immunohistochemistry (IHC) result is 3+, it is judged as positive; if it is 0 or 1+, it is judged as negative; if the IHC result is 2+, it is determined by detecting HER2 gene amplification using in situ hybridization (ISH) technique. The so-called HER2 low expression specifically refers to the subtypes IHC1+ and IHC2+/ISH-. Among them, the HER2-positive patients accounted for 20–25% of the total and were considered a poor prognostic factor in the past. However, with the evolution of anti-HER2 treatment drugs, the treatment pattern of HER2-positive advanced breast cancer was constantly rewritten. 6–8 Among them, monoclonal antibody drugs such as trastuzumab, pertuzumab and inituximab mainly target the extracellular binding domain of HER2 and block the heterodimerization of HER2 with other HER receptors by binding HER2, thus slowing down the growth of tumor. 9 Small molecular tyrosine kinase inhibitors (TKI), including Afatinib, Neratinib, Pyrotinib, Lapatinib and Tucatinib, target the intracellular tyrosine kinase region of HER2 to block signal transduction by inhibiting phosphorylation. 10 Despite achieving the breakthrough, nearly all patients with HER2-positive metastatic breast cancer (MBC) progressed eventually on anti-HER2 therapy due to the resistance. 11 For the patients with low-level expression of HER2 which is nearly 50% of BC patients, targeted drugs were not effective. 12 As a result, currently, the treatment of HER2-positive BC is still a difficult problem and a great challenge all over the world. One strategy is to apply antibody-drug conjugates (ADCs), improving the therapeutic index by combining the targeted specificity of monoclonal antibodies -Abstract Truncated-